Distribution of the Clinical Manifestations of Alpha 1 Antitrypsin Deficiency in Respiratory Outpatients from an Area of Northern Italy

Basic Science Investigations

Aiello M.a· Marchi L.b· Ferrarotti I.Frizzelli A.a· Pisi R.a· Calzetta L.a· Manari G.a· Pelà G.d,e· Russo A.f· Minerba R.f· Aloe R.f· Ranzieri S.g· Corradi M.g· Chetta A.a

Author affiliations

aDepartment of Medicine and Surgery, Respiratory Disease and Lung Function Unit, University of Parma, Parma, Italy
bDepartment of Food and Drug, University of Parma, Parma, Italy
cCenter for the Diagnosis of Inherited Alpha-1 Antitrypsin Deficiency, Department of Internal Medicine and Therapeutics, Pneumology Unit, University of Pavia, Pavia, Italy
dDepartment of Medicine and Surgery, University of Parma, Parma, Italy
eDepartment of General and Specialistic Medicine, University-Hospital of Parma, Parma, Italy
fLaboratory of Clinical Chemistry and Hematology, University Hospital of Parma, Parma, Italy
gDepartment of Medicine and Surgery, Occupational Medicine Unit, University of Parma, Parma, Italy

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Access via DeepDyve Unlimited fulltext viewing Of this article Organize, annotate And mark up articles Printing And downloading restrictions apply

Select

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview

Abstract of Basic Science Investigations

Received: December 17, 2021
Accepted: June 07, 2022
Published online: July 06, 2022

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 2

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: https://www.karger.com/RES

Abstract

Background: Alpha 1 antitrypsin deficiency (AATD) is an autosomal codominant genetic condition that affects Caucasians of the European population due to the presence of a deficient allele of the SERPINA1 gene. A frequency of about 1/5,000 individuals has been estimated in Italy. Objectives: The aim of the study was to evaluate the distribution of the clinical manifestations of severe and intermediate genetic AATD in the geographic area around Parma in Northern Italy. Method: 238 subjects were submitted to molecular analysis of the SERPINA1 gene, and data on anthropometric variables, smoking habits, number of packs per year, AAT serum concentration, and clinical manifestations were recorded and presented as mean ± SD or median values (1st quartile; 3rd quartile). Results: The results show a distribution of genetic AATD of 4.1% of the screened population in the area encompassing the city of Parma. PI*MS and PI*MZ were the most common genotypes at 40.9% and 28.2% of the population with genetic AATD, and asthma and emphysema were the most represented clinical manifestations. Conclusion: Our study allowed to increase the knowledge of the distribution of genetic AATD in Northern Italy providing information regarding frequencies of genotypes and clinical manifestations of the disorder.

© 2022 S. Karger AG, Basel

References Gadek J, Fells R, Zimmerman G, Rennard S, Crystal R. Antielastases of the human alveolar structures. Implications for the protease-antiprotease theory of emphysema. J Clin Invest. 1981;68:889–98. Aiello M, Frizzelli A, Pisi R, Fantin A, Ghirardini M, Marchi L, et al. Alpha-1 antitrypsin deficiency is significantly associated with atopy in asthmatic patients. J Asthma. 2020;22:1–8. Ranes J, Stoller JK. A review of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med. 2012;185(3):246–59. Poller W, Merklein F, Schneider-Rasp S, Haack A, Fechner H, Wang H, et al. Molecular characterisation of the defective alpha 1-antitrypsin alleles PI Mwurzburg (Pro369Ser), Mheerlen (Pro369Leu), and Q0lisbon (Thr68Ile). Eur J Hum Genet. 1999;7:321–31. Lomas DA, Hurst JR, Gooptu BJ. Update on alpha-1 antitrypsin deficiency: new therapies. J Hepatol. 2016 Aug;65(2):413–24. BrantlyPaul MLD, Paul BH, Miller RT, Falk M, Wu RG, Crystal RG. Clinical features and history of the destructive lung disease associated with alpha-1-antitrypsin deficiency of adults with pulmonary symptoms. Am Rev Respir Dis. 1988;138:327–36. de Serres FJ, Blanco I, Fernández-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in southern Europe: France, Italy, Portugal and Spain. Clin Genet. 2003;63(6):490–509. Ferrarotti I, Thun GA, Zorzetto M, Ottaviani S, Imboden M, Schindler C, et al. Serum levels and genotype distribution of α1-antitrypsin in the general population. Thorax. 2012;67(8):669–74. Miravitlles M, Dirksen A, Ferrarotti I, Koblizek V, Lange P, Mahadeva R, et al. European Respiratory Society statement: diagnosis and treatment of pulmonary disease in α1-antitrypsin deficiency. Eur Respir J. 2017;50:1700610. Gorrini M, Ferrarotti I, Lupi A, Bosoni T, Mazzola P, Scabini R, et al. Validation of a rapid, simple method to measure alpha1-antitrypsin in human dried blood spots. Clin Chem. 2006;52(5):899–901. Johansson SGO, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol. 2004;113:832–6. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. 2018. Available from: www.ginasthma.org. American Thoracic Society; European Respiratory Society. American Thoracic Society/European Respiratory Society statement: standards for the diagnosis and management of individuals with alpha-1 antitrypsin deficiency. Am J Respir Crit Care Med. 2003;168(7):818–900. Balderacchi AM, Barzon V, Ottaviani S, Corino A, Zorzetto M, Wencker M, et al. Comparison of different algorithms in laboratory diagnosis of alpha1-antitrypsin deficiency. Clin Chem Lab Med. 2021 Mar 5;59(8):1384–91. de Serres FJ, Blanco I. Prevalence of α1-antitrypsin deficiency alleles PI*S and PI*Z worldwide and effective screening for each of the five phenotypic classes PI*MS, PI*MZ, PI*SS, PI*SZ, and PI*ZZ: a comprehensive review. Ther Adv Respir Dis. 2012 Oct;6(5):277–95. Lomas D, Evans D, Finch J, Carrell R. The mechanism of Z alpha 1-antitrypsin accumulation in the liver. Nature. 1992;357:605–7. Luisetti M, Seersholm N. Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax. 2004;59:164–9. Italian registry of patients with alpha-1 antitrypsin deficiency. Available from: http://alfa1antitripsina.it/it. Giacopuzzi E, Laffranchi M, Berardelli R, Ravasio V, Ferrarotti I, Gooptu B, et al. Real-world clinical applicability of pathogenicity predictors assessed on SERPINA1 mutations in alpha-1-antitrypsin deficiency. Hum Mutat. 2018;39:1203–13. Annunziata A, Ferrarotti I, Coppola A, Lanza M, Imitazione P, Spinelli S, et al. Alpha-1 antitrypsin screening in a selected cohort of patients affected by chronic pulmonary diseases in Naples, Italy. J Clin Med. 2021 Apr 7;10(8):1546. Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report: GOLD executive summary. Eur Respir J. 2017;49(3):1700214. Article / Publication Details

First-Page Preview

Abstract of Basic Science Investigations

Received: December 17, 2021
Accepted: June 07, 2022
Published online: July 06, 2022

Number of Print Pages: 8
Number of Figures: 1
Number of Tables: 2

ISSN: 0025-7931 (Print)
eISSN: 1423-0356 (Online)

For additional information: https://www.karger.com/RES

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

留言 (0)

沒有登入
gif